Lixte Biotechnology Announces Initiation of a Phase I Trial of Its Lead Anti-Cancer Compound, LB-100
4/25/2013 11:30:35 AM
More...
|
Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
11/27/2012 9:07:08 AM
More...
|
Lixte Biotechnology Announces Increased Funding and FDA Allowance to Conduct A Phase I Trial of Its Lead Anti-Cancer Compound, LB-100
7/31/2012 12:30:00 PM
More...
|
Lixte Biotechnology Announces Submission of an IND to the FDA for Approval of a Clinical Trial of LB-100, a First-in-Class, Anti-Cancer Compound
5/1/2012 12:44:28 PM
More...
|
Lixte Biotechnology Receives US Patent for Its Proprietary Histone Deacetylase Inhibitor
4/4/2012 9:58:21 AM
More...
|
Lixte Biotechnology Announces Issuance of U.S. Patent for Agents for the Treatment of Neurodegenerative Diseases
1/9/2012 12:05:24 PM
More...
|
Lixte Biotechnology Compound LB-205 Reported to Have Therapeutic Potential for Gaucher Disease
12/19/2011 10:41:34 AM
More...
|
Lixte Biotechnology Announces Issuance of U.S. Patent for Lead Anti-Cancer Compound
9/22/2011 11:14:47 AM
More...
|
Lixte Biotechnology Announces New Appointment to Board of Directors, Robert B. Royds, M.B.
5/25/2011 10:26:36 AM
More...
|
Lixte Biotechnology Awarded Grant Under Qualifying Therapeutic Discovery Project from the U. S. Government
3/2/2011 9:28:21 AM
More...
|
|